LT3733187T - Chiralinis diarilo makrociklas ir jo panaudojimas vėžio gydymui - Google Patents
Chiralinis diarilo makrociklas ir jo panaudojimas vėžio gydymuiInfo
- Publication number
- LT3733187T LT3733187T LTEP20181616.2T LT20181616T LT3733187T LT 3733187 T LT3733187 T LT 3733187T LT 20181616 T LT20181616 T LT 20181616T LT 3733187 T LT3733187 T LT 3733187T
- Authority
- LT
- Lithuania
- Prior art keywords
- cancer treatment
- chiral diaryl
- macrocycle
- diaryl macrocycle
- chiral
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562195081P | 2015-07-21 | 2015-07-21 | |
| US201662302231P | 2016-03-02 | 2016-03-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3733187T true LT3733187T (lt) | 2024-12-10 |
Family
ID=57834656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP20181616.2T LT3733187T (lt) | 2015-07-21 | 2016-07-20 | Chiralinis diarilo makrociklas ir jo panaudojimas vėžio gydymui |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US20180325901A1 (lt) |
| EP (3) | EP4480543A3 (lt) |
| JP (1) | JP6817287B2 (lt) |
| KR (1) | KR102772574B1 (lt) |
| CN (1) | CN108026109B (lt) |
| AU (1) | AU2016296878B2 (lt) |
| BR (1) | BR112018001065A2 (lt) |
| CA (1) | CA2992324A1 (lt) |
| DK (2) | DK3325488T3 (lt) |
| ES (2) | ES2993492T3 (lt) |
| FI (1) | FI3733187T3 (lt) |
| HR (1) | HRP20241615T1 (lt) |
| HU (1) | HUE070316T2 (lt) |
| IL (1) | IL256868B (lt) |
| LT (1) | LT3733187T (lt) |
| MX (1) | MX383823B (lt) |
| PL (1) | PL3733187T3 (lt) |
| PT (1) | PT3733187T (lt) |
| RS (1) | RS66238B1 (lt) |
| RU (2) | RU2728579C2 (lt) |
| SI (1) | SI3733187T1 (lt) |
| SM (1) | SMT202400496T1 (lt) |
| WO (1) | WO2017015367A1 (lt) |
| ZA (1) | ZA201800416B (lt) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3636649T3 (pl) | 2014-01-24 | 2024-05-06 | Turning Point Therapeutics, Inc. | Diaryle makrocykliczne jako modulatory kinaz białkowych |
| ES2864839T3 (es) | 2015-07-02 | 2021-10-14 | Turning Point Therapeutics Inc | Macrociclos de diarilo quirales como moduladores de proteína quinasas |
| JP6917974B2 (ja) * | 2015-07-06 | 2021-08-11 | ターニング・ポイント・セラピューティクス・インコーポレイテッドＴｕｒｎｉｎｇ Ｐｏｉｎｔ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ジアリール大環状多形 |
| FI3733187T3 (fi) | 2015-07-21 | 2024-12-18 | Turning Point Therapeutics Inc | Kiraalinen diaryylimakrosykli ja sen käyttö syövän hoidossa |
| BR112019001607A2 (pt) | 2016-07-28 | 2019-04-30 | Tp Therapeutics, Inc. | inibidores macrocíclicos de quinases |
| TWI808958B (zh) * | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| CN107267458B (zh) * | 2017-07-06 | 2019-10-29 | 中南大学湘雅二医院 | 一种耐克唑替尼人的非小细胞肺癌细胞株h3122-cr23及其应用 |
| US11286264B2 (en) | 2017-07-28 | 2022-03-29 | Turning Point Therapeutics, Inc. | Macrocyclic compounds and uses thereof |
| CN109516999B (zh) * | 2017-11-01 | 2021-08-17 | 郑州泰基鸿诺医药股份有限公司 | 用作蛋白质激酶调节剂的化合物及其应用 |
| TW201927790A (zh) * | 2017-11-10 | 2019-07-16 | 美商安捷克斯製藥公司 | 作為trk激酶抑制劑之巨環化合物及其用途 |
| LT3728271T (lt) | 2017-12-19 | 2022-12-12 | Turning Point Therapeutics, Inc. | Makrocikliniai junginiai, skirti ligų gydymui |
| BR112020019399A2 (pt) * | 2018-03-28 | 2021-01-05 | Fochon Pharmaceuticals, Ltd. | Compostos macrocíclicos como inibidores de trk quinases |
| US11358973B2 (en) * | 2018-04-16 | 2022-06-14 | Shenzhen Targetrx, Inc. | Di(hetero)aryl macrocyclic compound for inhibiting protein kinase activity |
| WO2019206069A1 (zh) * | 2018-04-25 | 2019-10-31 | 北京普祺医药科技有限公司 | 一种二芳基巨环化合物、药物组合物以及其用途 |
| WO2019210835A1 (zh) * | 2018-05-04 | 2019-11-07 | 正大天晴药业集团股份有限公司 | 作为蛋白激酶调节剂的二芳基大环化合物 |
| AU2019364336B2 (en) | 2018-10-22 | 2023-11-16 | Alumis Inc. | TYK2 inhibitors and uses thereof |
| CN111171049B (zh) * | 2018-11-09 | 2021-06-04 | 山东轩竹医药科技有限公司 | 酪氨酸激酶抑制剂及其用途 |
| US20220411439A1 (en) * | 2019-06-19 | 2022-12-29 | Turning Point Therapeutics, Inc. | Polymorphs of a macrocyclic kinase inhibitor |
| US11666574B2 (en) * | 2019-11-27 | 2023-06-06 | Turning Point Therapeutics, Inc. | Combination therapy involving diaryl macrocyclic compounds |
| CN111689883B (zh) * | 2020-05-22 | 2022-02-11 | 上海应用技术大学 | 一种二芳基砜类化合物的合成方法 |
| JP2023528907A (ja) * | 2020-06-04 | 2023-07-06 | シンノハブ ファーマシューティカル カンパニー，リミティド | 大環状構造を有する化合物及びその使用 |
| CN115813930A (zh) * | 2021-08-17 | 2023-03-21 | 赛诺哈勃药业（成都）有限公司 | 大环化合物与mek抑制剂联用在用于治疗疾病药物中的用途 |
| WO2025217347A2 (en) * | 2024-04-11 | 2025-10-16 | Bristol-Myers Squibb Company | Process of preparing repotrectinib |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU679053B2 (en) | 1993-03-25 | 1997-06-19 | Pharmacia & Upjohn Company | Indoletetralins having dopaminergic activity |
| NO308798B1 (no) * | 1993-12-07 | 2000-10-30 | Lilly Co Eli | Proteinkinase-C-hemmere, anvendelse av samme for fremstilling av farmasøytika samt farmasøytisk formulering omfattende samme |
| RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| JP2004526676A (ja) * | 2000-12-08 | 2004-09-02 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | キナーゼ阻害剤として有用な大員複素環式化合物 |
| EP2065380A1 (en) * | 2007-08-22 | 2009-06-03 | F.Hoffmann-La Roche Ag | Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer |
| US8815872B2 (en) | 2008-09-08 | 2014-08-26 | Merck Patent Gmbh | Macrocyclics pyrimidines as aurora kinase inhibitors |
| PT2350075E (pt) | 2008-09-22 | 2014-06-09 | Array Biopharma Inc | Compostos imidazo[1,2b]piridazina substituídos como inibidores da trk cinase |
| AR074052A1 (es) | 2008-10-22 | 2010-12-22 | Array Biopharma Inc | Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa |
| CN102271515B (zh) | 2008-10-31 | 2014-07-02 | 健泰科生物技术公司 | 吡唑并嘧啶jak抑制剂化合物和方法 |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| WO2011045330A1 (en) | 2009-10-13 | 2011-04-21 | Tibotec Pharmaceuticals | Macrocyclic integrase inhibitors |
| SA111320200B1 (ar) | 2010-02-17 | 2014-02-16 | ديبيوفارم اس ايه | مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة |
| NZ604708A (en) | 2010-05-20 | 2015-05-29 | Array Biopharma Inc | Macrocyclic compounds as trk kinase inhibitors |
| US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
| EP2508607A1 (en) | 2011-04-07 | 2012-10-10 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for liver regeneration and for treatment of liver failure |
| WO2013001310A1 (en) * | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Macrocyclic compounds and their use as cdk8 inhibitors |
| EP2744331A4 (en) * | 2011-08-19 | 2015-01-21 | Merck Sharp & Dohme | METHOD AND INTERMEDIATE PRODUCTS FOR THE MANUFACTURE OF MACROLACTAMEN |
| CA2849999A1 (en) | 2011-09-30 | 2013-04-04 | Oncodesign S.A. | Macrocyclic flt3 kinase inhibitors |
| HUE034118T2 (en) | 2012-03-06 | 2018-01-29 | Pfizer | Macrocyclic derivatives for the treatment of proliferative diseases |
| RU2014140739A (ru) * | 2012-03-09 | 2016-04-27 | Лексикон Фармасьютикалз, Инк. | Соединения на основе имидазо[1, 2-b]пиридазина, композиции таких соединений и способы их применения |
| EP2834243B1 (en) | 2012-03-09 | 2018-04-25 | Lexicon Pharmaceuticals, Inc. | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE |
| GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| PL3636649T3 (pl) | 2014-01-24 | 2024-05-06 | Turning Point Therapeutics, Inc. | Diaryle makrocykliczne jako modulatory kinaz białkowych |
| ES2864839T3 (es) | 2015-07-02 | 2021-10-14 | Turning Point Therapeutics Inc | Macrociclos de diarilo quirales como moduladores de proteína quinasas |
| JP6917974B2 (ja) * | 2015-07-06 | 2021-08-11 | ターニング・ポイント・セラピューティクス・インコーポレイテッドＴｕｒｎｉｎｇ Ｐｏｉｎｔ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ジアリール大環状多形 |
| FI3733187T3 (fi) | 2015-07-21 | 2024-12-18 | Turning Point Therapeutics Inc | Kiraalinen diaryylimakrosykli ja sen käyttö syövän hoidossa |
| BR112019001607A2 (pt) | 2016-07-28 | 2019-04-30 | Tp Therapeutics, Inc. | inibidores macrocíclicos de quinases |
| TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| US11286264B2 (en) | 2017-07-28 | 2022-03-29 | Turning Point Therapeutics, Inc. | Macrocyclic compounds and uses thereof |
-
2016
- 2016-07-20 FI FIEP20181616.2T patent/FI3733187T3/fi active
- 2016-07-20 SI SI201631859T patent/SI3733187T1/sl unknown
- 2016-07-20 EP EP24198628.0A patent/EP4480543A3/en active Pending
- 2016-07-20 PT PT201816162T patent/PT3733187T/pt unknown
- 2016-07-20 DK DK16828471.9T patent/DK3325488T3/da active
- 2016-07-20 EP EP16828471.9A patent/EP3325488B1/en active Active
- 2016-07-20 RU RU2018106245A patent/RU2728579C2/ru active
- 2016-07-20 SM SM20240496T patent/SMT202400496T1/it unknown
- 2016-07-20 LT LTEP20181616.2T patent/LT3733187T/lt unknown
- 2016-07-20 RS RS20241314A patent/RS66238B1/sr unknown
- 2016-07-20 ES ES20181616T patent/ES2993492T3/es active Active
- 2016-07-20 BR BR112018001065-0A patent/BR112018001065A2/pt not_active Application Discontinuation
- 2016-07-20 AU AU2016296878A patent/AU2016296878B2/en active Active
- 2016-07-20 WO PCT/US2016/043132 patent/WO2017015367A1/en not_active Ceased
- 2016-07-20 JP JP2018502668A patent/JP6817287B2/ja active Active
- 2016-07-20 CN CN201680052319.6A patent/CN108026109B/zh active Active
- 2016-07-20 MX MX2018000718A patent/MX383823B/es unknown
- 2016-07-20 RU RU2020123800A patent/RU2020123800A/ru unknown
- 2016-07-20 HU HUE20181616A patent/HUE070316T2/hu unknown
- 2016-07-20 KR KR1020187002289A patent/KR102772574B1/ko active Active
- 2016-07-20 ES ES16828471T patent/ES2818528T3/es active Active
- 2016-07-20 EP EP20181616.2A patent/EP3733187B1/en active Active
- 2016-07-20 DK DK20181616.2T patent/DK3733187T3/da active
- 2016-07-20 PL PL20181616.2T patent/PL3733187T3/pl unknown
- 2016-07-20 CA CA2992324A patent/CA2992324A1/en active Pending
- 2016-07-20 HR HRP20241615TT patent/HRP20241615T1/hr unknown
- 2016-07-20 US US15/745,915 patent/US20180325901A1/en not_active Abandoned
-
2018
- 2018-01-11 IL IL256868A patent/IL256868B/en active IP Right Grant
- 2018-01-19 ZA ZA2018/00416A patent/ZA201800416B/en unknown
-
2020
- 2020-08-20 US US16/998,763 patent/US11452725B2/en active Active
-
2022
- 2022-08-15 US US17/819,858 patent/US12310968B2/en active Active
-
2025
- 2025-04-25 US US19/190,116 patent/US20250375451A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3733187T (lt) | Chiralinis diarilo makrociklas ir jo panaudojimas vėžio gydymui | |
| IL267158B (en) | Amino-triazopyridine compounds and their use in cancer treatment | |
| LT3134125T (lt) | Antikūno ir vaisto konjugatas bei jo panaudojimas vėžio gydymui | |
| IL256687B (en) | Isolated tau-binding antibody and use thereof in therapy and diagnosis | |
| LT3256218T (lt) | Kdm1a inhibitorius ir jo panaudojimas terapijoje | |
| IL259570A (en) | Combined therapy and their uses and methods | |
| PL3303632T3 (pl) | Terapeutyczne i diagnostyczne sposoby stosowane w nowotworze | |
| IL276733A (en) | Use of Aribolin in cancer treatment | |
| IL258979B (en) | The use of pyrimidine and pyridine history in the treatment of cancer | |
| GB201511382D0 (en) | Novel compounds and their use in therapy | |
| HRP20181490T1 (hr) | Spojevi 1, 3, 4-tiadiazola i njihova upotreba u liječenju raka | |
| SG11202104571RA (en) | 5-halouracil-modified micrornas and their use in the treatment of cancer | |
| IL259508A (en) | 1, 3, 4-thiadiazole compounds and their use for cancer treatment | |
| IL254139B (en) | Histamine-producing bacterial strains and their use in cancer | |
| IL261648A (en) | Cinnolin-4-amine compounds and their use in treating cancer | |
| DK3383871T3 (da) | 1,3,4-thiadiazolforbindelser og anvendelse deraf i behandling af cancer | |
| IL262143A (en) | Improvements in cancer treatment | |
| EP3380468B8 (en) | Bis-pyridazine compounds and their use in treating cancer | |
| SG10202001388YA (en) | Use of ureidomustine (bo-1055) in cancer treatment | |
| GB201514015D0 (en) | Novel pyridazinones and their use in the treatment of cancer | |
| LT3353164T (lt) | Diheteroarilpakeistieji 1,4-benzodiazepinai ir jų naudojimas vėžio gydymui | |
| GB201514018D0 (en) | Novel tricyclic compounds and their use in the treatment of cancer | |
| IL251825B1 (en) | Treatment of cancer and skin damage | |
| GB201510764D0 (en) | bis-Pyridazine compounds and their use in treating cancer | |
| HK1259160A1 (en) | Bis-pyridazine compounds and their use in treating cancer |